CardioVia
Device for Minimally Invasive Cardiac Access
Company Overview
Snapshot
Founded in December 2017 by Ziv Menshes, Or Hazan, Dr. Yonatan Demma, and Ran Eliaz, CardioVia operates with 1–10 employees. The company has secured funding across two rounds from NGT3 and EU Horizon 2020. In April 2025, CardioVia announced FDA clearance for its ViaOne system, marking a significant milestone in minimally invasive heart surface treatments.
Business overview
CardioVia is a medical device company focused on developing the ViaOne system, a technology designed for minimally invasive access to the heart's outer surface (pericardial space). This system aims to provide a safer entry route for treating prevalent cardiovascular diseases such as tamponade, effusion, and arrhythmias. CardioVia's technology ensures no needle exposure to the heart muscle, performing procedures in a controlled manner synchronized with heartbeats. The company operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers.
Strategic signal
In April 2025, CardioVia received FDA clearance for its ViaOne system. This regulatory approval is a critical validation of the company's technology, signaling its readiness for market entry and potential to revolutionize minimally invasive cardiac procedures. For investors, this clearance indicates significant progress towards commercialization and de-risks the product pathway, opening new opportunities in advanced cardiac care solutions.
Company Intelligence Q&A
- What is CardioVia's core product?
- CardioVia's core product is the ViaOne system, a medical device designed to provide minimally invasive access to the outer surface of the heart (pericardial space) for treating cardiovascular diseases.
- When was CardioVia founded and by whom?
- CardioVia was founded in December 2017 by Ziv Menshes, Or Hazan, Dr. Yonatan Demma, and Ran Eliaz.
- Has CardioVia received any regulatory approvals for its technology?
- Yes, in April 2025, CardioVia announced that it received U.S. Food and Drug Administration (FDA) clearance for its ViaOne system.
- Has CardioVia received any grants?
- In August 2019, CardioVia received a grant from EU Horizon 2020.
- What is the primary purpose of the ViaOne system?
- The ViaOne system is intended to ensure safe pericardial access, avoid complications, and increase procedural success for physicians while providing safety and assurance to patients during treatments for cardiovascular diseases.